NIBIOHN, Shionogi Discover Host Immune-dependent Novel Anti-coronavirus Antibody
Potential Candidate as Broad-spectrum Therapeutic Agent for Coronavirus Diseases Caused by Different Coronaviruses, including Variants – The National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN; Ibaraki-shi, Osaka; Director-general: Yoshihiro Yoneda), in partnership with Shionogi & Co., Ltd. (Chuo-ku, Osaka; President and CEO: Isao Teshirogi), has successfully identified a novel antiviral antibody for severe…
